Jaguar animal health exhibiting at veterinary cancer society collaborative conference for canalevia-ca1, the company's fda conditionally approved drug for chemotherapy-induced diarrhea (cid) in dogs

Canalevia®-ca1 is the first and only treatment for cid in dogs to receive any type of approval from the fda in december 2022, fda increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000 san francisco, ca / accesswire / march 30, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") under its jaguar animal health tradename for the veterinary market, today announced that the company is exhibiting at the veterinary cancer society (vcs) collaborative conference, which takes place april 19-22, 2023 in cancun, mexico, as part of ongoing promotional activities for canalevia-ca1 (crofelemer delayed-release tablets). canalevia-ca1, the company's u.s. food and drug administration (fda) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (cid) in dogs, is available from multiple leading veterinary distributors in the u.s. effective december 14, 2022, the fda's center for veterinary medicine increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000.
JAGX Ratings Summary
JAGX Quant Ranking